...
首页> 外文期刊>Psychopharmacology >Co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex induced by clozapine, the prototype atypical antipsychotic.
【24h】

Co-release of noradrenaline and dopamine from noradrenergic neurons in the cerebral cortex induced by clozapine, the prototype atypical antipsychotic.

机译:非原型抗精神病药氯氮平在大脑皮质的去甲肾上腺素能神经元中共同释放去甲肾上腺素和多巴胺。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

RATIONALE: Clozapine has been shown to increase extracellular dopamine (DA) and noradrenaline (NA) in the medial prefrontal cortex (mPFC). A recent study of ours suggested that extracellular DA in the PFC originates not only from dopaminergic but also from noradrenergic terminals, its release being controlled by alpha(2)-adrenoceptors. OBJECTIVES: Since clozapine binds to alpha(2)-adrenoceptors, the possibility that it might co-release DA and NA was studied. METHODS: By means of microdialysis coupled to HPLC with electrochemical detection, the effect of clozapine on extracellular DA and NA in the mPFC, densely innervated by DA and NA, was compared to that in the occipital cortex, equally innervated by NA but receiving few DA projections. RESULTS: Extracellular NA was found to be the same in the two cortices, consistent with homogeneous NA innervation. On the other hand, extracellular DA in the occipital cortex was only 29% lower than in the mPFC, in spite of the scarce dopaminergic innervation in the occipital cortex. Clozapine (10 mg/kg IP) increased extracellular DA and NA not only in the mPFC (by about 320% and 290%, respectively) but also in the occipital cortex (by 560% and 230%, respectively). Administration of the alpha(2)-agonist clonidine (0.15 mg/kg) reversed the effect of clozapine in both cortices, while the D(2)-agonist quinpirole (0.1 mg/kg IP) was ineffective. CONCLUSIONS: The results suggest that clozapine, by inhibiting alpha(2)-adrenoceptors, co-releases DA and NA from noradrenergic terminals in the occipital cortex and that the same mechanism might be responsible for the concomitant increase of the two monoamines in the mPFC.
机译:理由:氯氮平已显示可增加额前内侧皮层(mPFC)的细胞外多巴胺(DA)和去甲肾上腺素(NA)。我们的一项最新研究表明,PFC中的细胞外DA不仅源自多巴胺能,而且还源自去甲肾上腺素能终端,其释放受α(2)-肾上腺素受体控制。目的:由于氯氮平与α(2)-肾上腺素能受体结合,因此研究了其可能共同释放DA和NA的可能性。方法:通过微渗析与HPLC结合电化学检测,将氯氮平对被DA和NA密集支配的mPFC中细胞外DA和NA的影响与与被NA同样支配但接受很少DA的枕叶皮质中的影响预测。结果:发现两个皮质中的细胞外NA相同,这与均匀的NA神经支配相一致。另一方面,尽管枕皮质中缺乏多巴胺能神经支配,但枕皮质中的细胞外DA仅比mPFC低29%。氯氮平(10 mg / kg IP)不仅在mPFC中(分别增加了约320%和290%),而且在枕皮质中也增加了细胞外DA和NA(分别增加了560%和230%)。给予α(2)-激动剂可乐定(0.15 mg / kg)可以逆转氯氮平在两个皮质中的作用,而D(2)-激动剂喹吡罗(0.1 mg / kg IP)无效。结论:结果表明,氯氮平通过抑制α(2)-肾上腺素能受体,从枕叶皮质的去甲肾上腺素末端共释放DA和NA,并且相同的机制可能导致mPFC中两种单胺的同时增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号